Long COVID Linked to Dopamine Neuron Injury in New Brain Study

A new study published in eBioMedicine provides fresh insights into the biological basis of long COVID, identifying measurable damage to the brain's dopamine system. Researchers from the Brain Health Imaging Centre and the University of Toronto utilized positron emission tomography (PET) imaging to examine 24 adults suffering from persistent neuropsychiatric symptoms. The findings revealed significantly lower levels of VMAT2—a marker for dopamine neuron integrity—in the striatum, a region critical for motivation, reward, and motor control.

The study observed a 16% to 20% reduction in dopamine nerve terminal density among long COVID participants compared to healthy controls. Senior study author Dr. Jeffrey Meyer suggests that this loss of dopamine-releasing neurons explains common debilitating symptoms such as lack of motivation, motor slowing, and cognitive impairment. This research shifts the focus of long COVID investigation from mere symptom cataloging to identifying specific, measurable brain-network phenotypes, marking a significant evolution in understanding post-viral neurological manifestations.

While the research indicates an association rather than direct causation, these results offer a potential roadmap for future clinical trials. By reframing long COVID as a disorder involving the dopamine system, scientists may explore the repurposing of existing medications that target dopamine metabolism or function. Further longitudinal research is required to determine the clinical significance and permanence of these changes, but the identification of this target offers a new avenue for developing effective treatments to restore quality of life for patients.